Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression

/PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics...

Related Keywords

Montreal ,Quebec ,Canada ,Toronto ,Ontario ,Ottawa ,Canadians ,Canadian ,Roger Mcintyre ,Rogers Mcintyre ,Joshua Rosenblat ,Research To Reality Conference ,Feasibility Of Braxia Institute ,Braxia Scientific Corp ,Excellence Inc ,Health Canada Special Access Program ,Health Canada ,Canadian Rapid Treatment Center ,Health Canada Approved ,Braxia Institute ,Chief Medical ,Scientific Officer ,Braxia Scientific ,Special Access Program ,Braxia Health ,Canadian Rapid Treatment Centre ,Controlled Drugs ,Substances Act ,Restated Listing Statement ,Pharmaceuticals ,Health Care Amp Hospitals ,Otc ,Mallcap ,Medical Pharmaceuticals ,Mental Health ,New Products Amp Services ,Clinical Trials Amp Medical Discoveries ,